Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | CASP1 | P29466 | 2/20 | 0.71 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | ACP1 | P24666 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459871 | 0.82 | HRH4 (0.55) | HSD17B10CASP1HRH4KDM4EALDH1A1 | |
| SCHEMBL1457962 | 0.82 | HPGD (0.66) | HSD17B10CASP1HRH4KDM4EALDH1A1 | |
| SCHEMBL1458615 | 0.82 | HPGD (0.66) | HSD17B10CASP1HRH4KDM4EALDH1A1 | |
| SCHEMBL1458918 | 0.82 | HPGD (0.66) | HSD17B10CASP1HRH4KDM4EALDH1A1 | |
| SCHEMBL1458839 | 0.82 | HPGD (0.66) | HSD17B10CASP1HRH4KDM4EALDH1A1 | |
| SCHEMBL15940580 | 0.81 | CASP1 (0.64) | HSD17B10CASP1HRH4KDM4EALDH1A1 | |
| SCHEMBL1458040 | 0.78 | HPGD (0.58) | HRH4KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1459027 | 0.78 | HPGD (0.58) | HRH4KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1458680 | 0.78 | HPGD (0.58) | HRH4KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL6235741 | 0.76 | ALDH1A1 (0.57) | HSD17B10CASP1HRH4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999042463-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | claimed |
| WO-1999042461-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | claimed |
| EP-4082547-B1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING TREATMENTS OF AN EYE | AVEDRO INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4082547-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING TREATMENTS OF AN EYE | Avedro, INC. (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3226871-B1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING TREATMENTS OF AN EYE | AVEDRO INC (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-107206003-B | Systems, methods, and compositions for cross-linking treatment of the eye | 艾维德洛公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3858356-A2 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING | Avedro, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-2999471-B1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING | AVEDRO INC (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200046835-A1 | Systems, Methods, and Compositions For Cross-Linking Treatments of an Eye | AVEDRO, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3226871-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING TREATMENTS OF AN EYE | Avedro, INC. (US) | 2017-10-11 | — | — | EP | disclosed |
| CN-107206003-A | Systems, methods, and compositions for cross-linking treatment of the eye | 艾维德洛公司 | 2017-09-26 | — | — | CN | disclosed |
| US-20160175442-A1 | Systems, Methods, and Compositions For Cross-Linking Treatments of an Eye | AVEDRO, INC. | 2016-06-23 | — | — | US | disclosed |
| WO-2016090016-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING TREATMENTS OF AN EYE | AVEDRO, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2999471-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING | Avedro, INC. (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20140343480-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING | AVEDRO, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-6548499-B1 | N-(1-Azabicyclo(2.2.2)octanyl-3-pyridinyl)-3-(2-pyridinyl)-2 -quinoxalinamine, for example; treating various chemokine mediated diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-1999042463-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999042461-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046835-A1 | Systems, Methods, and Compositions For Cross-Linking Treatments of an Eye | CS, FECH, PNPO | HSD17B10 1468/4885CASP1 4098/4885HRH4 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.